comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-26 10:51:47 - browse：46843

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： American taxpayers paid $1.8 trillion in health care costs in 2022

WSS

Stories you might have missed in 2023: health, science, medicine

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Profiling embryos to choose those with higher IQs is almost a reality

In shift, Texas to cover initial consult for Afghan baby's gene therapy

FDA advisers back CAR

As AI in medicine takes off, can 'human in the loop' prevent harm?

focus

comprehensive

hotspot

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Nonprofit, backed by Microsoft, to certify AI tools in health care

Bright Health sells Medicare Advantage business to Molina

Pushing for an NIH office for post

BioMarin wins approval for gene therapy to treat hemophilia A

Medicare Advantage overpayments discussion gets experts fired up

In Memoriam: Notable people who died in 2023

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Duchenne breakthrough therapy leaves behind pioneering families

Fauci's latest grilling in Congress: 9 hours, behind closed doors

explore

Gene therapy denied for Afghan refugee whose father aided U.S.

As AI in medicine takes off, can 'human in the loop' prevent harm?

Mayo Clinic partners with supercomputer AI firm Cerebras at JPM

Medicare Advantage coverage denials need scrutiny, senators say

UCLA team creates talking throat patch for voice disorders

President Biden's budget: Here's what you might have missed

focus

focus

hotspot

hotspot